Previous 10 | Next 10 |
home / stock / akblf / akblf news
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that Claus Steensen Sølje will take up the position as Executive Vice President, Chief Financial Officer (CFO) and member of the Board of Management no later than 1 June 2023. He succeeds Søren Jelert, whose decision to leave ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that its Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (AIT) tablet has been accepted for review by the National Medical Products Administration (NMPA) in China. The BLA, for treatmen...
ALK's ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2022 annual report (ESEF-version ALK-2022-12-31-en attached). Following a solid Q4, full-year results exceeded initial expectations and were in line with the most recent outlook. ALK expects to con...
U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents PR Newswire – ODACTRA is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons ...
ALK-Abelló A/S press release (OTCPK:AKBLF): Q1 GAAP EPS of $0.70. Revenue of $1.16B (+13.7% Y/Y). Outlook for 2022, ALK is maintaining its full-year outlook: Revenue is still expected to grow 8-12% in local currencies with tablet sales up by ~20%; EBITDA is still expected to increa...
ALK-Abelló A/S press release (OTCPK:AKBLF): Q4 EBITDA more than doubled to DKK136M vs. DKK64M, reflecting higher sales, improved gross margins and a modest increase in capacity costs. Revenue of DKK 1.1B (+11.0% Y/Y). For 2022, ALK expects revenue growth of 8-12% and a further impro...
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have ...
ALK-Abelló A/S (OTCPK:AKBLF): Q2 Operating profit was at DKK 48M Revenue of DKK 866M Press Release For further details see: ALK-Abelló A/S reports Q2 results
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - Acquisition Supports ALK's Commitment to Provide Innovative Solutions to Address the Needs of Healthcare Providers, Including ENTs, and their Patien...
U.S. FDA Approves ALK's RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis - RAGWITEK is now indicated to treat ragweed ...
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...
08 February 2024 ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK expects to continue its growth trajectory and earning...
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK ( ALKB:DC / OMX: ALK B / AKBLF ) announced today that it has completed the first part of its phase 1 clinical trial...